ACP-104 in Acutely Psychotic Subjects With Schizophrenia
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled parallel-group, 6-week study,
evaluating two dose levels of ACP-104 or Placebo twice a day in patients with schizophrenia
who are experiencing an acute psychotic episode.